Nxera Pharma Co Ltd (SOLTF) Q4 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Time has come, so we will now begin the financial results briefing of Nexara Pharma for FY 2024. Thank you for taking time out of your busy schedule to join us today. I am Nomura, CFO. I will be the moderator. Today, we have Chris Cargill, CEO, Dr. Matt Barnes, President of Heptaris and Head of UKRD, and Dr. Makoto Sugita, Chief Medical Officer and President and CEO of Nexara Pharma Japan. simultaneous interpretation is provided. Please click on the earth icon in the lower right corner of the screen or click the details button and then the globe icon and select either Japanese or English. If you choose off, you will hear the speaker's original voice. Today, we will explain the progress of our business using the materials in the first half, followed by a Q&A session in the second half. The presentation materials will be shown on the screen and are also available on our website. If you want a copy, please access our website by selecting IR News from the Shareholders and Investors tab in the upper right corner of the website. For the Q&A session in the second half, institutional investors, analysts, and members of the media are welcome to raise your hands and ask questions during the Q&A session. For all others, please submit your questions via the Q&A button. Questions can be submitted any time during the webinar and will be answered as time permits during the Q&A session later. So we will start the briefing, I will first explain the full year financial results, followed by an operational update from Chris, Japan and APAC commercial business by Sugita and R&D progress, mainly in the UK by Matt. Finally, Chris will explain our FY 2025 goals and medium to long term objectives. Please turn to page five of the presentation. This is page 5. This is the summary of the financ...